İnvaziv Meme Kanserinde Cerrahi Tedavi
Özet
Günümüzde invaziv meme kanseri tedavisi, tümör biyolojisine göre şekillenen bireyselleştirilmiş ve multidisipliner bir yaklaşım gerektirmektedir. Tarihsel süreçte, William Stewart Halsted’in geniş doku rezeksiyonunu savunan radikal mastektomisiyle başlayan cerrahi evrim, Bernard Fisher’ın meme kanserini sistemik bir hastalık olarak tanımlamasıyla daha az invaziv yöntemlere yönelmiştir. David Patey’nin modifiye radikal mastektomiyi literatüre kazandırmasının ardından yapılan çalışmalar, meme koruyucu cerrahinin (MKC) mastektomi ile benzer sağkalım oranları sağladığını ve kabul edilebilir lokal nüks oranlarıyla kozmetik sonuçları iyileştirdiğini ortaya koymuştur. Güncel dönemde ise onkoplastik cerrahi teknikler ve gelişmiş rekonstrüksiyon yöntemleri, hastaların yaşam kalitesini ve memnuniyetini belirgin şekilde artırmaktadır. Aksilla cerrahisinde de benzer bir küçülme (deescalation) yaşanmış; rutin aksiller disseksiyonun yerini sentinel lenf nodu biyopsisi (SLNB) almıştır. NSABP B-32 ve ACOSOG Z0011 gibi çığır açan klinik çalışmalar, klinik olarak aksillası negatif olan veya düşük nodal yüke sahip uygun hastalarda aksiller disseksiyonun yapılmamasının onkolojik açıdan güvenli olduğunu kanıtlamıştır. Ayrıca, cerrahi öncesi uygulanan neoadjuvan kemoterapi, hem tümör boyutunu küçülterek meme korunmasını kolaylaştırmakta hem de pozitif lenf nodlarının negatifleşmesini sağlayarak hastaları gereksiz aksiller disseksiyon morbiditelerinden korumaktadır. Sonuç olarak modern cerrahi, tolere edilebilir maksimum tedaviden, etkili minimum tedaviye doğru başarılı bir dönüşüm sergilemektedir.
Today, the treatment of invasive breast cancer requires an individualized and multidisciplinary approach determined by tumor biology. Historically, the surgical evolution began with William Stewart Halsted's radical mastectomy, which favored extensive tissue resections. However, following Bernard Fisher’s paradigm shift defining breast cancer as a systemic disease, therapeutic approaches shifted toward less invasive interventions. The introduction of modified radical mastectomy by David Patey and subsequent landmark long-term trials demonstrated that breast-conserving surgery (BCS) offers equivalent survival rates to total mastectomy while significantly improving cosmetic outcomes and patient satisfaction. Currently, oncoplastic surgery and advanced reconstruction techniques further enhance the quality of life and body image for patients. Axillary management has undergone a similar de-escalation, where routine axillary dissection (AD) has been largely replaced by sentinel lymph node biopsy (SLNB). Crucial clinical trials, such as NSABP B-32 and ACOSOG Z0011, established that omitting axillary dissection is oncologically safe in clinically node-negative patients or those with a low nodal burden. Furthermore, the strategic use of neoadjuvant chemotherapy successfully downstages tumors to facilitate BCS and promotes nodal conversion, effectively sparing patients from severe surgical morbidities. Ultimately, modern breast cancer surgery reflects a successful transition from maximum tolerable treatment to minimum effective therapy.
Referanslar
Ebru Şen, Vahit Özmen. (2022) Meme. İçin Schwartz Cerrahinin ilkeleri F. Charles Brunıcardi çeviri ed Mahir Özmen Güneş Tıp Kitabevi. McGraw-Hill, 11. Baskı p:541-612.
Kirby I. Bland, Edward M. Copeland III, Suzanne Klimberg (2017). History of the therapy of breast cancer. In: The breast comprehensive management of benign and malignant diseases Eds: Kirby I. Bland, Edward M. Copeland III, V. Suzanne Klimberg, William J Gradishar. Elsevier Philadelphia. p:1-19.
Halsted WS. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg. 1894;20:497
Meyer W. An improved method of the radical operation for carcinoma of the breast. Med Rec. 1894; 46:746.
Patey Dh, Dyson Wh. The prognosis of carcinoma of the breast in relation to the type of operation performed. Br J Cancer. 1948;2:7–13
Kirby I. Bland, Helena R. Chang, Edward M. Copeland III (2017). Modified radical mastectomy and simple mastectomy. In: The breast comprehensive management of benign and malignant diseases. Eds: Kirby I. Bland, Edward M. Copeland III, V. Suzanne Klimberg, William J Gradishar. Elsevier Philadelphia. p:443-463.
Auchincloss H. Significance of location and number of axillary metastases in carcinoma of the breast. Ann Surg. 1963;158:37-46.
De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy‐radiotherapy approach in locally advanced (T3b–T4) breast cancer. Cancer Chemother Pharmacol. 1978;1:53‐59
Fisher B, Bauer M, Margolese R, R Poisson, Y Pilch, C Redmond, E Fisher, N Wolmark, M Deutsch, E Montague, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985 ;312 :665-673.
Fisher B, Anderson S, Bryant J, Richard G Margolese, Melvin Deutsch, Edwin R Fisher, Jong-Hyeon Jeong, Norman Wolmark. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002 ;347 :1233-1241.
Jeeyeon Lee, Youngtae Bae, Werner Audretsch. Combination of two local flaps for large defects after breast conserving surgery Breast. Breast 2012 Apr;21(2):194-8.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature. 2000:17; 406:747-52.
Andrea Sisti , Maria T Huayllani, Daniel Boczar , David J Restrepo , Aaron C Spaulding , Gabriel Emmanuel , Sanjay P Bagaria , Sarah A cLaughlin , Alexander S Parker , Antonio J Forte Breast cancer in women: a descriptive analysis of the national cancer database Acta Biomed 2020 May 11;91(2):332-341.
Skjerven HK, Danielsen AS, Schlichting E, Sahlberg KK, Hofvind S. Surgical treatment of breast cancer in Norway 2003-2018. Tidsskr Nor Laegeforen. 2020 Oct 26;140(15).
Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-9.
Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994; 220:391-398.
Alice Chung, Armando E. Giuliano (2017). Lymhatic mapping and sentinel lymphadenectomy for breast cancer. In: The breast comprehensive management of benign and malignant diseases. Eds: Kirby I. Bland, Edward M. Copeland III, V. Suzanne Klimberg, William J Gradishar. Elsevier Philadelphia. p:604-631.
Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Wolmark N. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927-33.
Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010; 251:595–600.
Noguchi M, Inokuchi M, Noguchi M, Morioka E, Ohno Y, Kurita T. Axillary surgery for breast cancer: past, present, and future. Breast Cancer. 2021;28:9-15.
Wong SL, Edwards MJ, Chao C, Tuttle TM, Noyes RD, Carlson DJ, Cerrito PB, McMasters KM. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg. 2001;192:684-9.
Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426–432.
Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Morrow M, Hunt KK. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg. 2016;264:413-20.
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomized multicenter, open-label, phase 3 noninferiority trial. Lancet Oncol. 2014;15: 1303–10.
Savolt A, Peley G, Polgar C, Udvarhelyi N, Rubovszky G, Kovacs E, et al. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla -surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol. 2017;43: 672–9.
Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23–1): 10-year follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2018;19: 1385–93.
Montserrat Solá José A Alberro, Manuel Fraile, Pilar Santesteban, Manuel Ramos, Rafael Fabregas, Antonio Moral, Blas Ballester, Sergi Vidal. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013;20:120-127.
C Lanng , J Hoffmann, H Galatius, U Engel. Assessment of clinical palpation of the axilla as a criterion for performing the sentinel node procedure in breast cancer. Eur J Surg Oncol, 2007;33:281-4.
Magnoni F, Galimberti V, Corso G, Intra M, Sacchini V, Veronesi P. Axillary surgery in breast cancer: An updated historical perspective. Semin Oncol. 2020;47 :341-352.
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al; Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–1461.
Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14: 609–618.
Boileau JF, Poirier B, Basik M, Holloway CM, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015; 33:258–264.
Brackstone M, Baldassarre FG, Perera FE, Cil T, Chavez Mac Gregor M, Dayes IS, Engel J, Horton JK, King TA, Kornecki A, George R, SenGupta SK, Spears PA, Eisen AF. Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. J Clin Oncol. 2021: 20;39: 3056-3082.
Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node- Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016;34;1072-8.
Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M; Panelists of the St Gallen Consensus Conference. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021; 32:1216-1235.
400. Almahariq MF, Levitin R, Quinn TJ, Chen PY, Dekhne N, Kiran S, Desai A, Benitez P, Jawad MS, Gustafson GS, Dilworth JT. Omission of Axillary Lymph Node Dissection is Associated with Inferior Survival in Breast Cancer Patients with Residual N1 Nodal Disease Following Neoadjuvant Chemotherapy. Ann Surg Oncol. 2021;28:930-940.
500. Cabıoğlu N, Karanlık H, Yıldırım N, Müslümanoğlu M, Çakmak Karadeniz G, Trabulus Can D, Tükenmez M, Ersoy YE, Uras C, Zengel B, Emiroğlu S, Polat AK, Yeniay L, Özkurt E, Kara H, İbiş K, Aydıner A, Özmen V, İğci A. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study. Eur J Surg Oncol. 2021;47:2506-2514.
Stefan Aebi , Per Karlsson , Irene L Wapnir. Locally advanced breast cancer Breast. 2022;62:1:58-62
Lynda Wyld, Christos Markopoulos, Marjut Leidenius, Elżbieta Senkus-Konefka, Eds. (2018) Breast cancer management for surgeons, Springer.
Moo TA, Sanford R, Dang C, Morrow M. Overview of Breast Cancer Therapy. PET Clin. 2018;13:339-354.
Petruolo O, Sevilimedu V, Montagna G, Le T, Morrow M, Barrio AV How Often Does Modern Neoadjuvant Chemotherapy Downstage Patients to Breast-Conserving Surgery? Ann Surg Oncol. 2021;28:287-294
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019: 14;380:617-628.
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017: 1;376:2147-2159.
Cavalcante FP, Millen EC, Zerwes FP, Novita GG. Progress in Local Treatment of Breast Cancer: A Narrative Review. Rev Bras Ginecol Obstet. 2020;42:356-364.
Aoife J Lowery , Malcolm R Kell, Ronan W Glynn, Michael J Kerin, Karl J Sweeney. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133:831-41.
De Boniface J, Szulkin R, Johansson ALV. Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status: A Swedish National 6-Year Follow-up of 48 986 Women. JAMA Surg. 2021:156;628-637.
Van Maaren MC, de Munck L, de Bock GH, Jobsen JJ, van Dalen T, Linn SC, Poortmans P, Strobbe LJA, Siesling S. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016; 17:1158-1170.
Flanagan MR, Zabor EC, Romanoff A, Fuzesi S, Stempel M, Mehrara BJ, Morrow M, Pusic AL, Gemignani ML. A Comparison of Patient-Reported Outcomes After Breast-Conserving Surgery and Mastectomy with Implant Breast Reconstruction. Ann Surg Oncol. 2019; 26:3133-3140.
Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 1985:1;56:979-90.
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005:17;366:2087-2106.
Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Schinagl D, Oei B et all. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet a randomised phase 3 trial. Lancet Oncol. 2015 Jan;16(1):47-56.
Amy E. Rivere, V. Suzanne Klimberg, Kirby I. Bland (2017) Breast Conservation Therapy for Invasive Breast Cancer. In: The breast comprehensive management of benign and malignant diseases, Eds: Kirby I. Bland, Edward M. Copeland III, V. Suzanne Klimberg, William J Gradishar. Elsevier Philadelphia. p:462-476.
Montagna G, Morrow M. Breast-conserving Surgery Without Radiation Therapy for Invasive Cancer. Clin Breast Cancer. 2021;21:112-119.
Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004; 351:971–977.
Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382–2387.
Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM; PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16: 266-73.
Gabriella Squeo , Jessica K Malpass , Max Meneveau , Rajesh Balkrishnan , Raj P Desai , Courtney Lattimore , Roger T Anderson , Shayna L Showalter. Long-term Impact of CALGB 9343 on Radiation Utilization. 2020;256:577-583.
V. Suzanne Klimberg, Kelly K. Hunt. (2021) Diseases of the Breast. In: Sabiston textbook of surgery: the biological basis of modern surgical practice. Ed: Courtney Townsend, Elsevier Philadelphia. p:809-855.
Rudy Leon De Wilde, Rajesh Devassy, Luz Angela Torres-de la Roche, Harald Krentel, Vlad Tica, Cristina Cezar. Guidance and Standards for Breast Cancer Care in Europe. J Obstet Gynaecol India. 2020;70:330-336.
Houssami N, Macaskill P, Marinovich ML, Morrow M. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol. 2014;21:717-30.
Li Y, Lu S, Zhang Y, Wang S, Liu H. Loco-regional recurrence trend and prognosis in young women with breast cancer according to molecular subtypes: analysis of 1099 cases. World J Surg Oncol. 2021,13;19:113.
McGuire A, Lowery AJ, Kell MR, Kerin MJ, Sweeney KJ. Locoregional Recurrence Following Breast Cancer Surgery in the Trastuzumab Era: A Systematic Review by Subtype. Ann Surg Oncol. 2017;24:3124-3132.
Michael Co , Thomas Liu , Jason Leung , Chung Hin Li , Theo Tse , Michael Wong , Ava Kwong Breast Conserving Surgery for BRCA Mutation Carriers-A Systematic Review. Clin Breast Cancer. 2020;20: 244-250.
Crown A, Handy N, Rocha FG, Grumley JW. Oncoplastic reduction mammaplasty, an effective and safe method of breast conservation. Am J Surg. 2018;215 :910-915.
Kaufman CS. Increasing Role of Oncoplastic Surgery for Breast Cancer. Curr Oncol Rep. 2019,14 ;21:111
Crown A, Wechter DG, Grumley JW. Oncoplastic Breast- Conserving Surgery Reduces Mastectomy and Postoperative Re-excision Rates. Ann Surg Oncol. 2015;22:3363-8.
Chen JY, Huang YJ, Zhang LL, Yang CQ, Wang K. J Comparison of Oncoplastic Breast-Conserving Surgery and Breast-Conserving Surgery Alone: A Meta-Analysis. Breast Cancer. 2018;21:321-329.
Jonczyk MM, Jean J, Graham R, Chatterjee A. Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis. Breast Cancer Res Treat. 2019; 173: 267-274.
Asban A, Homsy C, Chen L, Fisher C, Losken A, Chatterjee A. A cost- utility analysis comparing large volume displacement oncoplastic surgery to mastectomy with single stage implant reconstruction in the treatment of breast cancer. Breast. 2018;41: 159-164
Galimberti V, Vicini E, Corso G, Morigi C, Fontana S, Sacchini V, Veronesi P. Nipple-sparing and skin-sparing mastectomy: Review of aims, oncological safety and contraindications. Breast. 2017;34 : S82-S84.
Jones C, Lancaster R. Evolution of Operative Technique for Mastectomy. Surg Clin North Am. 2018;98:835-844.
Daar DA, Abdou SA, Rosario L, Rifkin WJ, Santos PJ, Wirth GA, Lane KT. Is There a Preferred Incision Location for Nipple-Sparing Mastectomy? A Systematic Review and Meta-Analysis. Plast Reconstr Surg. 2019;143 :906 -919.
Galimberti V, Morigi C, Bagnardi V, Corso G, Vicini E. Oncological Outcomes of Nipple-Sparing Mastectomy: A Single-Center Experience of 1989 Patients. Ann Surg Oncol. 2018:25:3849-3857.
Hoffman DI, Santos PMG, Goldbach M, Keele LJ, Taunk NK, Bogen HS, Burkbauer L, Jankowitz RC, Fosnot J, Wu LC, Freedman GM, Tchou JC. Immediate Breast Reconstruction for Inflammatory Breast Cancer: Trends in Use and Clinical Outcomes 2004-2016. Ann Surg Oncol. 2021; 28:8789-8801.
Momoh AO, Griffith KA, Hawley ST, Morrow M, Ward KC, Hamilton AS, Shumway D, Katz SJ, Jagsi R. Postmastectomy Breast Reconstruction: Exploring Plastic Surgeon Practice Patterns and Perspectives. Plast Reconstr Surg. 2020;145:865-876.
M Riis. Modern surgical treatment of breast cancer. Ann Med Surg. 2020, 23;56:95-107
Piccotti F, Rybinska I, Scoccia E, Morasso C, Ricciardi A, et al. Lipofilling in Breast Oncological Surgery: A Safe Opportunity or Risk for Cancer Recurrence? Int J Mol Sci. 2021: 3; 22:3737.
Kirby I. Bland, Jorge I De La Torre, Edward M. Copeland III, V. Suzanne Klimberg, Cr I. Bonet I, Lu Is O. Vasconez (2017). General principles of mastectomy: evaluation and therapeutic options. In: The breast comprehensive management of benign and malignant diseases Eds: Kirby I. Bland, Edward M. Copeland III, V. Suzanne Klimberg, William J Gradishar. Elsevier Philadelphia. p:386-421.
Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002 Oct 17;347(16):1227-32.
Clough KB, Nasr R, Nos C, Vieira M, Inguenault C, Poulet B. New anatomical classification of the axilla with implications for sentinel node biopsy. Br J Surg. 2010; 97:1659-65.
Shivers S, Cox C, Leight G, Beauchamp D, Blumencranz P, Ross M, Reintgen D. Final results of the Department of Defense multicenter breast lymphatic mapping trial. Ann Surg Oncol. 2002; 9:248-55.
Ahmed M. Al Maksoud, Adel K. Barsoum, Mohammed M. Moneer. Langer's arch: a rare anomaly affects axillary lymphadenectomy. J Surg Case Rep. 2015;12: rjv159.
